International Journal of Obstetrics and Gynecology

Objective To analyze the effect of labetalol plus magnesium sulfate treatment on maternal and infant prognosis in patients with gestational hypertension. Methods 62 patients diagnosed with gestational hypertension in the obstetrics department of our hospital from April 2019 to April 2022 were selected. The patients were randomly divided into the control group and the experimental group as the research objects. 31 patients in the experimental group were treated with labetalol plus magnesium sulfate, and the control group was only treated with magnesium sulfate. In order to exclude other interventions, the experimental patients in both groups were treated with Routine basic care was implemented, and data recording and analysis were performed during the experiment. Results showed that the total effective rates of patients treated with labetalol plus magnesium sulfate and those treated with magnesium sulfate alone were 96.8% (30/31) and 80.6% (25/31), respectively, P<0.05 (the difference was statistically significant) . The pregnancy outcome of the experimental group was significantly better than that of the control group. Because the pregnancy outcome was positively correlated with the prognosis of mother and baby, it was concluded that the prognosis of the mother and baby in the experimental group was significantly better than that in the control group (P<0.05). Conclusion The application of labetalol plus magnesium sulfate in the treatment of gestational hypertension can significantly improve the therapeutic effect and improve the prognosis of mother and child, which is worthy of clinical promotion.

Gestational hypertension; Magnesium sulfate; Labetalol; Pregnancy outcome; Maternal and infant prognosis